2025 -- H 5615 SUBSTITUTE A
========
LC001419/SUB A
========
S T A T E O F R H O D E I S L A N D
IN GENERAL ASSEMBLY
JANUARY SESSION, A.D. 2025
____________
A N A C T
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT
Introduced By: Representative Matthew S. Dawson
Date Introduced: February 26, 2025
Referred To: House Health & Human Services
(Dept. of Health)
It is enacted by the General Assembly as follows:
1 SECTION 1. Sections 21-28-1.02, 21-28-3.20 and 21-28-3.20.1 of the General Laws in
2 Chapter 21-28 entitled "Uniform Controlled Substances Act" are hereby amended to read as
3 follows:
4 21-28-1.02. Definitions. [Effective January 1, 2023; see Sunset Provision note.]
5 Unless the context otherwise requires, the words and phrases as defined in this section are
6 used in this chapter in the sense given them in the following definitions:
7 (1) “Acute pain” means the normal, predicted physiological response to a noxious
8 chemical, thermal, or mechanical stimulus and typically is associated with invasive procedures,
9 trauma, and disease. Acute pain is generally pain of less than thirty (30) days duration.
10 (1)(2) “Administer” refers to the direct application of controlled substances to the body of
11 a patient or research subject by:
12 (i) A practitioner Practitioners, or, in his or her their presence by his or her their authorized
13 agent; or
14 (ii) The patient or research subject at the direction and in the presence of the practitioner
15 whether the application is by injection, inhalation, ingestion, or any other means.
16 (2)(3) “Agent” means an authorized person who acts on behalf of, or at the direction of, a
17 manufacturer, wholesaler, distributor, or dispenser; except that these terms do not include a
18 common or contract carrier or warehouse operator when acting in the usual and lawful course of
19 the carrier’s or warehouse operator’s business.

1 (3)(4) “Apothecary” means a registered pharmacist as defined by the laws of this state and,
2 where the context requires, the owner of a licensed pharmacy or other place of business where
3 controlled substances are compounded or dispensed by a registered pharmacist; and includes
4 registered assistant pharmacists as defined by existing law, but nothing in this chapter shall be
5 construed as conferring on a person who is not registered as a pharmacist any authority, right, or
6 privilege that is not granted to him or her by the pharmacy laws of the state.
7 (4)(5) “Automated data processing system” means a system utilizing computer software
8 and hardware for the purposes of record keeping.
9 (6) “Chronic intractable pain” means pain that is: excruciating; constant; incurable, and of
10 such severity that it dominates virtually every conscious moment; and/or produces mental and
11 physical debilitation. A diagnosis and written documentation of chronic intractable pain made by a
12 physician licensed in the State of Rhode Island specializing in pain management, oncology, or
13 similar specialty defined in regulations shall constitute proof that the patient suffers from chronic
14 intractable pain.
15 (7) “Chronic pain” means pain of greater than ninety (90) days duration, excluding chronic
16 intractable pain.
17 (5)(8) “Computer” means programmable electronic device capable of multi-functions,
18 including, but not limited to: storage, retrieval, and processing of information.
19 (6)(9) “Control” means to add a drug or other substance or immediate precursor to a
20 schedule under this chapter, whether by transfer from another schedule or otherwise.
21 (7)(10) “Controlled substance” means a drug, substance, immediate precursor, or synthetic
22 drug in schedules I — V of this chapter. The term shall not include distilled spirits, wine, or malt
23 beverages, as those terms are defined or used in chapter 1 of title 3, nor tobacco.
24 (8)(11) “Co-prescribing” means issuing a prescription for an opioid antagonist along with
25 a prescription for an opioid analgesic.
26 (9)(12) “Counterfeit substance” means a controlled substance that, or the container or
27 labeling of which, without authorization bears the trademark, trade name, or other identifying mark,
28 imprint, number, or device, or any likeness of them, of a manufacturer, distributor, or dispenser,
29 other than the person or persons who in fact manufactured, distributed, or dispensed the substance
30 and that thereby falsely purports or is represented to be the product of, or to have been distributed
31 by, the other manufacturer, distributor, or dispenser, or which substance is falsely purported to be
32 or represented to be one of the controlled substances by a manufacturer, distributor, or dispenser.
33 (10)(13) “CRT” means cathode ray tube used to impose visual information on a screen.
34 (11)(14) “Deliver” or “delivery” means the actual, constructive, or attempted transfer of a
LC001419/SUB A - Page 2 of 20

1 controlled substance or imitation controlled substance, whether or not there exists an agency
2 relationship.
3 (12)(15) “Department” means the department of health of this state.
4 (13)(16) “Depressant or stimulant drug” means:
5 (i) A drug that contains any quantity of:
6 (A) Barbituric acid or derivatives, compounds, mixtures, or preparations of barbituric acid;
7 and
8 (B) “Barbiturate” or “barbiturates” includes all hypnotic and/or somnifacient drugs,
9 whether or not derivatives of barbituric acid, except that this definition shall not include bromides
10 and narcotics.
11 (ii) A drug that contains any quantity of:
12 (A) Amphetamine or any of its optical isomers;
13 (B) Any salt of amphetamine and/or desoxyephedrine or any salt of an optical isomer of
14 amphetamine and/or desoxyephedrine, or any compound, mixture, or preparation of them.
15 (iii) A drug that contains any quantity of coca leaves. “Coca leaves” includes cocaine, or
16 any compound, manufacture, salt, derivative, mixture, or preparation of coca leaves, except
17 derivatives of coca leaves, that do not contain cocaine, ecgonine, or substance from which cocaine
18 or ecgonine may be synthesized or made.
19 (iv) Any other drug or substance that contains any quantity of a substance that the attorney
20 general of the United States, or the director of health, after investigation, has found to have, or by
21 regulation designates as having, a potential for abuse because of its depressant or stimulant effect
22 on the central nervous system.
23 (14)(17) “Director” means the director of health.
24 (15)(18) “Dispense” means to deliver, distribute, leave with, give away, or dispose of a
25 controlled substance to the ultimate user or human research subject by or pursuant to the lawful
26 order of a practitioner, including the packaging, labeling, or compounding necessary to prepare the
27 substance for that delivery.
28 (16)(19) “Dispenser” is a practitioner who delivers a controlled substance to the ultimate
29 user or human research subject.
30 (17)(20) “Distribute” means to deliver (other than by administering or dispensing) a
31 controlled substance or an imitation controlled substance and includes actual constructive, or
32 attempted transfer. “Distributor” means a person who so delivers a controlled substance or an
33 imitation controlled substance.
34 (18)(21) “Downtime” means that period of time when a computer is not operable.
LC001419/SUB A - Page 3 of 20

1 (19)(22) “Drug addicted person” means a person who exhibits a maladaptive pattern of
2 behavior resulting from drug use, including one or more of the following: impaired control over
3 drug use; compulsive use; and/or continued use despite harm, and craving.
4 (20)(23) “Drug Enforcement Administration” means the Drug Enforcement
5 Administration, United States Department of Justice or its successor.
6 (21)(24) “Federal law” means the Comprehensive Drug Abuse Prevention and Control Act
7 of 1970, (84 stat. 1236) (see generally 21 U.S.C. § 801 et seq.), and all regulations pertaining to
8 that federal act.
9 (22)(25) “Hardware” means the fixed component parts of a computer.
10 (23)(26) “Hospital” means an institution as defined in chapter 17 of title 23.
11 (24)(27) “Imitation controlled substance” means a substance that is not a controlled
12 substance, that by dosage unit, appearance (including color, shape, size, and markings), or by
13 representations made, would lead a reasonable person to believe that the substance is a controlled
14 substance and, which imitation controlled substances contain substances that if ingested, could be
15 injurious to the health of a person. In those cases when the appearance of the dosage unit is not
16 reasonably sufficient to establish that the substance is an “imitation controlled substance” (for
17 example in the case of powder or liquid), the court or authority concerned should consider, in
18 addition to all other logically relevant factors, the following factors as related to “representations
19 made” in determining whether the substance is an “imitation controlled substance”:
20 (i) Statement made by an owner, possessor, transferor, recipient, or by anyone else in
21 control of the substance concerning the nature of the substance, or its use or effect.
22 (ii) Statements made by the owner, possessor, or transferor, to the recipient that the
23 substance may be resold for substantial profit.
24 (iii) Whether the substance is packaged in a manner reasonably similar to packaging of
25 illicit controlled substances.
26 (iv) Whether the distribution or attempted distribution included an exchange of or demand
27 for money or other property as consideration, and whether the amount of the consideration was
28 substantially greater than the reasonable value of the non-controlled substance.
29 (25)(28) “Immediate precursor” means a substance:
30 (i) That the director of health has found to be, and by regulation designated as being, the
31 principal compound used, or produced primarily for use, in the manufacture of a controlled
32 substance;
33 (ii) That is an immediate chemical intermediary used or likely to be used in the manufacture
34 of those controlled substances; and
LC001419/SUB A - Page 4 of 20

1 (iii) The control of which is necessary to prevent, curtail, or limit the manufacture of that
2 controlled substance.
3 (26)(29) “Laboratory” means a laboratory approved by the department of health as proper
4 to be entrusted with controlled substances and the use of controlled substances for scientific and
5 medical purposes and for the purposes of instruction.
6 (27)(30) “Manufacture” means the production, preparation, propagation, cultivation,
7 compounding, or processing of a drug or other substance, including an imitation controlled
8 substance, either directly or indirectly or by extraction from substances of natural origin, or
9 independently by means of chemical synthesis or by a combination of extraction and chemical
10 synthesis and includes any packaging or repackaging of the substance or labeling or relabeling of
11 its container in conformity with the general laws of this state except by a practitioner as an incident
12 to his or her administration or dispensing of the drug or substance in the course of his or her
13 professional practice.
14 (28)(31) “Manufacturer” means a person who manufactures but does not include an
15 apothecary who compounds controlled substances to be sold or dispensed on prescriptions.
16 (29)(32) “Marijuana” means all parts of the plant cannabis sativa L., whether growing or
17 not; the seeds of the plant; the resin extracted from any part of the plant; and every compound,
18 manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin, but shall not
19 include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the
20 seeds of the plant, any other compound, manufacture, salt, derivative, mixture, or preparation of
21 mature stalks, (except the resin extracted from it), fiber, oil or cake, or the sterilized seed from the
22 plant which is incapable of germination. Marijuana shall not include “industrial hemp” or
23 “industrial hemp products” which satisfy the requirements of chapter 26 of title 2, nor shall it
24 include products that have been approved for marketing as a prescription medication by the U.S.
25 Food and Drug Administration and legally prescribed.
26 (30)(33) “Narcotic drug” means any of the following, whether produced directly or
27 indirectly by extraction from substances of vegetable origin, or independently by means of
28 chemical synthesis or by a combination of extraction and chemical synthesis:
29 (i) Opium and opiates.
30 (ii) A compound, manufacture, salt, derivative, or preparation of opium or opiates.
31 (iii) A substance (and any compound, manufacture, salt, derivative, or preparation of it)
32 that is chemically identical with any of the substances referred to in subsections (30)(i) and (30)(ii).
33 (iv) Any other substance that the attorney general of the United States, or his or her
34 successor, or the director of health, after investigation, has found to have, and by regulation
LC001419/SUB A - Page 5 of 20

1 designates as having, a potential for abuse similar to opium and opiates.
2 (31)(34) “Official written order” means an order written on a form provided for that
3 purpose by the Drug Enforcement Administration under any laws of the United States making
4 provision for an official form, if order forms are authorized and required by federal law, and if no
5 order form is provided then on an official form provided for that purpose by the director of health.
6 (32) “Opiate” means any substance having an addiction-forming or addiction-sustaining
7 liability similar to morphine or being capable of conversion into a drug having addiction-forming
8 or addiction-sustaining liability.
9 (33)(35) “Opioid analgesics” means and includes, but is not limited to, the medicines
10 buprenophine, medications butorphanol, codeine, hydrocodone, hydromorphone, levorphanol,
11 meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine,
12 propoxyphene as well as their brand names, isomers, and combinations, or other medications
13 approved by the department.
14 (34)(36) “Opioid antagonist” means naloxone hydrochloride and any other drug approved
15 by the United States Food and Drug Administration for the treatment of opioid overdose.
16 (37) “Opioid therapy” means to prescribe, administer, or dispense controlled substances
17 not prohibited by law for a therapeutic purpose to a person diagnosed and treated by a practitioner
18 for a condition by any route of administration.
19 (35)(38) “Opium poppy” means the plant of the species papaver somniferum L., except the
20 seeds of the plant.
21 (36)(39) “Ounce” means an avoirdupois ounce as applied to solids and semi-solids, and a
22 fluid ounce as applied to liquids.
23 (37)(40) “Person” means any corporation, association, partnership, or one or more
24 individuals.
25 (38)(41) “Physical dependence” means a state of adaptation that is manifested by a drug
26 class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction,
27 decreasing blood level of the drug, and/or administration of an antagonist.
28 (39)(42) “Poppy straw” means all parts, except the seeds, of the opium poppy, after
29 mowing.
30 (40)(43) “Practitioner” means:
31 (i) A physician, osteopath, dentist, chiropodist, veterinarian, scientific investigator, or other
32 person licensed, registered, or permitted to distribute, dispense, conduct research with respect to or
33 to administer a controlled substance in the course of professional practice or research in this state.
34 (ii) A pharmacy, hospital, or other institution licensed, registered or permitted to distribute,
LC001419/SUB A - Page 6 of 20

1 dispense, conduct research with respect to, or to administer a controlled substance in the course of
2 professional practice or research in this state.
3 (41)(44) “Printout” means a hard copy produced by computer that is readable without the
4 aid of any special device.
5 (42)(45) “Production” includes the manufacture, planting, cultivation, growing, or
6 harvesting of a controlled substance.
7 (43)(46) “Researcher” means a person authorized by the director of health to conduct a
8 laboratory as defined in this chapter.
9 (44)(47) “Sell” includes sale, barter, gift, transfer, or delivery in any manner to another, or
10 to offer or agree to do the same.
11 (45)(48) “Software” means programs, procedures, and storage of required information
12 data.
13 (46)(49) “Synthetic drugs” means any synthetic cannabinoids or piperazines or any
14 synthetic cathinones as provided for in schedule I.
15 (50) “Therapeutic purpose” means the use of controlled substances for the treatment of
16 pain in appropriate doses as indicated by the patient’s medical record. Any other use is
17 nontherapeutic.
18 (47)(51) “Ultimate user” means a person who lawfully possesses a controlled substance for
19 his or her own use or for the use of a member of his or her household, or for administering to an
20 animal owned by him or her or by a member of his or her household.
21 (48)(52) “Wholesaler” means a person who sells, vends, or distributes at wholesale, or as
22 a jobber, broker agent, or distributor, or for resale in any manner in this state any controlled
23 substance.
24 21-28-3.20. Authority of practitioner to prescribe, administer, and dispense.
25 (a)(1) A practitioner Practitioners, in good faith and in the course of his or her their
26 professional practice only, may prescribe, administer, and dispense controlled substances, or he or
27 she may cause the controlled substances to be administered by a nurse or intern under his or her
28 their direction and supervision after completing an assessment of pain experienced by a patient.
29 (2) Opioid therapy must only be initiated for acute pain unresponsive to non-opioid
30 therapies or if, based on clinical assessment, benefits of opioid therapy for acute pain management
31 outweigh risks.
32 (2)(3) When issuing an initial a prescription for an opiate opioid to an adult patient, a
33 practitioner shall not exceed the maximum daily dose requirements established by the department
34 of health must prescribe the lowest effective dosage of an immediate-release opioid in a quantity
LC001419/SUB A - Page 7 of 20

1 sufficient to treat the expected duration of pain. A practitioner shall not write an initial prescription
2 for an opioid in a quantity exceeding a seven (7)-day supply for treatment of acute pain.
3 (3)(4) Except as provided in subsection (a)(4) of this section, a practitioner shall not issue
4 an opiate prescription to a minor for more than twenty (20) doses at any time. Prior to issuing an
5 opiate prescription to a minor, a practitioner shall discuss with the parent or guardian of the minor
6 the risks associated with opiate use and the reasons why the prescription is necessary. The
7 practitioner shall document his or her discussion with the parent or guardian in the medical record.
8 (4)(5) Notwithstanding the limitations referenced in subsection (a)(3) of this section, if, in
9 the professional medical judgment of a practitioner, a greater dosage or supply of an opiate is
10 required to treat the minor patient’s acute medical condition or is necessary for the treatment of
11 chronic pain management, sickle cell related pain, intractable pain treatment as defined in chapter
12 37.4 of title 5, pain associated with a cancer diagnosis, or for palliative care, then the practitioner
13 may issue a prescription for the quantity needed to treat the acute medical condition, chronic pain,
14 sickle cell related pain, intractable pain, pain associated with a cancer diagnosis, or pain
15 experienced while the patient is in palliative care, provided that this dosage shall not exceed the
16 maximum daily dosage permitted for the treatment of this pain as set forth in the department of
17 health regulations. The medical condition triggering the prescription of an opiate shall opioid must
18 be documented in the minor patient’s medical record, and the practitioner shall must indicate that
19 a non-opiate non-opioid alternative was not appropriate to address the medical condition.
20 (5) Notwithstanding subsections (a)(2) and (a)(3) of this section, this section shall not apply
21 to medications designed for the treatment of substance abuse or opioid dependence.
22 (b) The prescription-monitoring drug monitoring program shall must be reviewed prior to
23 starting any opioid. A prescribing practitioner, or designee as authorized by § 21-28-3.32(a)(3),
24 shall must review the patient’s prescribed controlled substance use in the prescription-monitoring
25 drug monitoring program prior to refilling or initiating opioid therapy with an intrathecal pump,
26 including opioid therapy delivered through an intrathecal pump. The review must include gathering
27 a history of any prescribed methadone and buprenorphine. For patients the prescribing practitioner
28 is maintaining being maintained on continuous opioid therapy for pain for three (3) months or
29 longer, the prescribing practitioner shall must review information from the prescription-monitoring
30 drug monitoring program at least every three (3) months. Documentation of that review shall must
31 be noted in the patient’s medical record.
32 (c) The director of health shall develop regulations for prescribing practitioners on
33 appropriate limits of opioid use in acute pain management. Initial prescriptions of opioids for acute
34 pain management of outpatient adults shall not exceed thirty (30) morphine milligram equivalents
LC001419/SUB A - Page 8 of 20

1 (MMEs) total daily dose per day for a maximum total of twenty (20) doses, and, for pediatric
2 patients, the appropriate opioid dosage maximum per the department of health.
3 (d)(c) For the purposes of this section, acute pain management shall must not include
4 management or treatment for chronic intractable pain management, pain associated with a cancer
5 diagnosis, pain related to sickle cell disease, palliative or nursing home end-of-life care, intractable
6 or chronic intractable pain, as provided in § 5-37.4-2, or other exception exceptions in accordance
7 with department of health regulations.
8 (e) Subsection (c) shall not apply to medications designed for the treatment of substance
9 abuse or opioid dependence.
10 (f) On or before September 1, 2018, the director of health shall develop, and make available
11 to healthcare practitioners, information on best practices for co-prescribing opioid antagonists to
12 patients. The best practices information shall identify situations in which co-prescribing an opioid
13 antagonist may be appropriate, including, but not limited to:
14 (1) In conjunction with a prescription for an opioid medication, under circumstances in
15 which the healthcare practitioner determines the patient is at an elevated risk for an opioid drug
16 overdose;
17 (2) In conjunction with medications prescribed pursuant to a course of medication therapy
18 management for the treatment of a substance use disorder involving opioids; or
19 (3) Under any other circumstances in which a healthcare practitioner identifies a patient as
20 being at an elevated risk for an opioid drug overdose.
21 (g) The best practices information developed pursuant to subsection (f) of this section shall
22 include guidelines for determining when a patient is at an elevated risk for an opioid drug overdose,
23 including, but not limited to, situations in which the patient:
24 (1) Meets the criteria provided in the opioid overdose toolkit published by the federal
25 substance abuse and mental health service administration;
26 (2) Is receiving high-dose, extended-release, or long-acting opioid medications;
27 (3) Has a documented history of an alcohol or substance use disorder, or a mental health
28 disorder;
29 (4) Has a respiratory ailment or other co-morbidity that may be exacerbated by the use of
30 opioid medications;
31 (5) Has a known history of intravenous drug use or misuse of prescription opioids;
32 (6) Has received emergency medical care or been hospitalized for an opioid overdose; or
33 (7) Uses opioids with antidepressants, benzodiazepines, alcohol, or other drugs.
34 (h) On or before September 1, 2018, the director of health and the secretary of the executive
LC001419/SUB A - Page 9 of 20

1 office of health and human services shall develop strategies that include:
2 (1) Allowing practitioners in non-pharmacy settings to prescribe and dispense opioid
3 antagonists; and
4 (2) Ensuring that opioid antagonists that are distributed in a non-pharmacy setting are
5 eligible for reimbursement from any health insurance carrier, as defined under chapters 18, 19, 20,
6 and 41 of title 27, and the Rhode Island medical assistance program, as defined under chapter 7.2
7 of title 42.
8 (d) The director of health may promulgate regulations for practitioners on opioid use in
9 pain management.
10 21-28-3.20.1. Authority of practitioner to prescribe, administer, and dispense —
11 Cancer, palliative care, and chronic intractable pain.
12 (a) A practitioner, in good faith and in the course of his or her professional practice
13 managing pain associated with a cancer diagnosis, palliative or nursing home care, intractable or
14 chronic intractable pain as provided in § 5-37.4-2, or other condition allowed by department of
15 health regulations pursuant to the exception in § 21-28-3.20(d), may prescribe, administer, and
16 dispense controlled substances without regard to the CDC Clinical Practice Guideline for
17 Prescribing Opioids for Pain—United States, 2022.
18 (b) The director of health may promulgate those rules and regulations necessary to
19 effectuate the provisions of this section and ensure that rules governing pain management
20 associated with a cancer diagnosis, palliative or nursing home care, intractable or chronic
21 intractable pain as provided in § 5-37.4-2, or other condition allowed by department of health
22 regulations pursuant to the exception created in § 21-28-3.20(d), shall:
23 (1) Take into consideration the individualized needs of patients covered by this section;
24 and
25 (2) Make provisions for practitioners, acting in good faith, and in the course of their
26 profession, and managing pain associated with their patients’ illness to use their best judgment
27 notwithstanding any statute, rule, or regulation to the contrary. may prescribe, administer, or
28 dispense controlled substances not prohibited by law for a therapeutic purpose to a person
29 diagnosed and treated by a practitioner for a condition resulting in chronic intractable pain, if this
30 diagnosis and treatment has been documented in the practitioner’s medical records.
31 (b) Concern about a patient’s substance use disorder or the possibility of a substance use
32 disorder in and of itself is not a reason to withhold or prohibit prescribing, administering, or
33 dispensing controlled substances for the therapeutic purpose of treatment of a person for chronic
34 intractable pain. Provided, however, practitioners must check the patient’s prescribed controlled
LC001419/SUB A - Page 10 of 20

1 substances use in the prescription drug monitoring program, verify the patient's methadone use,
2 refer the patient to a substance use disorder specialist, as appropriate, and enter into a written patient
3 treatment agreement in accordance with regulations promulgated by the department.
4 (c) The provisions of subsection (a) of this section provide no authority to a practitioner to
5 prescribe, administer, or dispense controlled substances to a person the practitioner knows or should
6 know to be using the prescribed, administered, or dispensed controlled substance
7 nontherapeutically.
8 (d) Nothing in this section shall be construed to prohibit a practitioner or pharmacist from
9 denying a prescription based on their best clinical judgment.
10 (e) Nothing in this section shall deny the right of the director to deny, revoke, or suspend
11 the license of any practitioner or discipline any practitioner who:
12 (1) Prescribes, administers, or dispenses a controlled substance that is nontherapeutic in
13 nature or nontherapeutic in the manner in which it is prescribed, administered, or dispensed, or fails
14 to keep complete and accurate ongoing records of the diagnosis and treatment plan;
15 (2) Fails to keep complete and accurate records of controlled substances received,
16 prescribed, dispensed, and administered, and disposal of drugs as required by law or of controlled
17 substances scheduled in the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21
18 U.S.C. § 801 et seq. A practitioner shall keep records of controlled substances received, prescribed,
19 dispensed and administered, and disposal of these drugs shall include the date of receipt of the
20 drugs, the sale or disposal of the drugs by the practitioner, the name and address of the person
21 receiving the drugs, and the reason for the disposal or the dispensing of the drugs to the person;
22 (3) Writes false or fictitious prescriptions for controlled substances as prohibited by law,
23 or for controlled substances scheduled in the Comprehensive Drug Abuse Prevention and Control
24 Act of 1970, 21 U.S.C. § 801 et seq.; or
25 (4) Prescribes, administers, or dispenses in a manner that is inconsistent with provisions of
26 the law, or the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21 U.S.C. § 801
27 et seq., any controlled substance.
28 (f) The director of health may promulgate those rules and regulations necessary to
29 effectuate the provisions of this section.
30 SECTION 2. Chapter 5-37.4 of the General Laws entitled "Intractable Pain Treatment" is
31 hereby repealed in its entirety.
32 CHAPTER 5-37.4
33 Intractable Pain Treatment
34 5-37.4-1. Title.
LC001419/SUB A - Page 11 of 20

1 This chapter shall be known and may be cited as the “Intractable Pain Treatment Act.”
2 5-37.4-2. Definitions.
3 For purposes of this chapter:
4 (1) “Chronic intractable pain” means pain that is: excruciating; constant; incurable, and of
5 such severity that it dominates virtually every conscious moment; and/or produces mental and
6 physical debilitation. A diagnosis and written documentation of chronic intractable pain made by a
7 physician licensed in the state of Rhode Island specializing in pain management, oncology, or
8 similar specialty defined in regulations shall constitute proof that the patient suffers from chronic
9 intractable pain.
10 (2) “Director” means the director of the department of health of the state of Rhode Island.
11 (3) “Intractable pain” means a pain state that persists beyond the usual course of an acute
12 disease or healing of an injury or results from a chronic disease or condition that causes continuous
13 or intermittent pain over a period of months or years. Unless the context clearly indicates otherwise,
14 the term intractable pain includes chronic intractable pain.
15 (4) “Practitioner” means healthcare professionals licensed to distribute, dispense, or
16 administer controlled substances in the course of professional practice as defined in § 21-28-
17 1.02(41).
18 (5) “Therapeutic purpose” means the use of controlled substances for the treatment of pain
19 in appropriate doses as indicated by the patient’s medical record. Any other use is nontherapeutic.
20 5-37.4-3. Controlled substances.
21 (a) A practitioner may prescribe, administer, or dispense controlled substances not
22 prohibited by law for a therapeutic purpose to a person diagnosed and treated by a practitioner for
23 a condition resulting in intractable pain, if this diagnosis and treatment has been documented in the
24 practitioner’s medical records. No practitioner shall be subject to disciplinary action by the board
25 solely for prescribing, administering, or dispensing controlled substances when prescribed,
26 administered, or dispensed for a therapeutic purpose for a person diagnosed and treated by a
27 practitioner for a condition resulting in intractable pain, if this diagnosis and treatment has been
28 documented in the practitioner’s medical records.
29 (b) The provisions of subsection (a) of this section do not apply to those persons being
30 treated by a practitioner for chemical dependency because of their use of controlled substances not
31 related to the therapeutic purposes of treatment of intractable pain.
32 (c) The provisions of subsection (a) of this section provide no authority to a practitioner to
33 prescribe, administer, or dispense controlled substances to a person the practitioner knows or should
34 know to be using the prescribed, administered, or dispensed controlled substance
LC001419/SUB A - Page 12 of 20

1 nontherapeutically.
2 (d) Drug dependency or the possibility of drug dependency in and of itself is not a reason
3 to withhold or prohibit prescribing, administering, or dispensing controlled substances for the
4 therapeutic purpose of treatment of a person for intractable pain, nor shall dependency relating
5 solely to this prescribing, administering, or dispensing subject a practitioner to disciplinary action
6 by the director.
7 (e) In coordination with §§ 21-28-3.20 and 21-28-3.20.1, the director of health may
8 promulgate rules and regulations necessary to effectuate the purpose of this chapter and ensure that
9 patients with intractable or chronic intractable pain are treated or referred to an appropriate
10 specialist.
11 (f) Nothing in this section shall be construed to prohibit a practitioner or pharmacist from
12 denying a prescription based on their best clinical judgment.
13 (g) Nothing in this section shall deny the right of the director to deny, revoke, or suspend
14 the license of any practitioner or discipline any practitioner who:
15 (1) Prescribes, administers, or dispenses a controlled substance that is nontherapeutic in
16 nature or nontherapeutic in the manner in which it is prescribed, administered, or dispensed, or fails
17 to keep complete and accurate ongoing records of the diagnosis and treatment plan;
18 (2) Fails to keep complete and accurate records of controlled substances received,
19 prescribed, dispensed, and administered, and disposal of drugs as required by law or of controlled
20 substances scheduled in the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21
21 U.S.C. § 801 et seq. A practitioner shall keep records of controlled substances received, prescribed,
22 dispensed and administered, and disposal of these drugs shall include the date of receipt of the
23 drugs, the sale or disposal of the drugs by the practitioner, the name and address of the person
24 receiving the drugs, and the reason for the disposal or the dispensing of the drugs to the person;
25 (3) Writes false or fictitious prescriptions for controlled substances as prohibited by law,
26 or for controlled substances scheduled in the Comprehensive Drug Abuse Prevention and Control
27 Act of 1970, 21 U.S.C § 801 et seq.; or
28 (4) Prescribes, administers, or dispenses in a manner which is inconsistent with provisions
29 of the law, or the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21 U.S.C. §
30 801 et seq., any controlled substance.
31 (h) A practitioner may administer a controlled substance prescribed by a practitioner and
32 not prohibited by law for a therapeutic purpose to a person diagnosed and treated by a practitioner
33 for a condition resulting in intractable pain, if this diagnosis and treatment has been documented in
34 the practitioner’s medical records. No practitioner shall be subject to disciplinary action by the
LC001419/SUB A - Page 13 of 20

1 director solely for administering controlled substances when prescribed or dispensed for a
2 therapeutic purpose for a person diagnosed and treated by a practitioner for a condition resulting in
3 intractable pain, if this diagnosis and treatment has been documented in the practitioner’s medical
4 records of the patient.
5 SECTION 3. Section 21-28-1.02 of the General Laws in Chapter 21-28 entitled "Uniform
6 Controlled Substances Act" is hereby repealed.
7 21-28-1.02. Definitions. [Effective until January 1, 2023; see Sunset Provision note.]
8 Unless the context otherwise requires, the words and phrases as defined in this section are
9 used in this chapter in the sense given them in the following definitions:
10 (1) “Administer” refers to the direct application of controlled substances to the body of a
11 patient or research subject by:
12 (i) A practitioner, or, in his or her presence by his or her authorized agent; or
13 (ii) The patient or research subject at the direction and in the presence of the practitioner
14 whether the application is by injection, inhalation, ingestion, or any other means.
15 (2) “Agent” means an authorized person who acts on behalf of, or at the direction of, a
16 manufacturer, wholesaler, distributor, or dispenser; except that these terms do not include a
17 common or contract carrier or warehouse operator when acting in the usual and lawful course of
18 the carrier’s or warehouse operator’s business.
19 (3) “Apothecary” means a registered pharmacist as defined by the laws of this state and,
20 where the context requires, the owner of a licensed pharmacy or other place of business where
21 controlled substances are compounded or dispensed by a registered pharmacist; and includes
22 registered assistant pharmacists as defined by existing law, but nothing in this chapter shall be
23 construed as conferring on a person who is not registered as a pharmacist any authority, right, or
24 privilege that is not granted to him or her by the pharmacy laws of the state.
25 (4) “Automated data processing system” means a system utilizing computer software and
26 hardware for the purposes of record keeping.
27 (5) “Certified law enforcement prescription drug diversion investigator” means a certified
28 law enforcement officer assigned by his or her qualified law enforcement agency to investigate
29 prescription drug diversion.
30 (6) “Computer” means programmable electronic device capable of multi-functions,
31 including, but not limited to: storage, retrieval, and processing of information.
32 (7) “Control” means to add a drug or other substance or immediate precursor to a schedule
33 under this chapter, whether by transfer from another schedule or otherwise.
34 (8) “Controlled substance” means a drug, substance, immediate precursor, or synthetic
LC001419/SUB A - Page 14 of 20

1 drug in schedules I — V of this chapter. The term shall not include distilled spirits, wine, or malt
2 beverages, as those terms are defined or used in chapter 1 of title 3, nor tobacco.
3 (9) “Co-prescribing” means issuing a prescription for an opioid antagonist along with a
4 prescription for an opioid analgesic.
5 (10) “Counterfeit substance” means a controlled substance that, or the container or labeling
6 of which, without authorization bears the trademark, trade name, or other identifying mark, imprint,
7 number, or device, or any likeness of them, of a manufacturer, distributor, or dispenser, other than
8 the person or persons who in fact manufactured, distributed, or dispensed the substance and that
9 thereby falsely purports or is represented to be the product of, or to have been distributed by, the
10 other manufacturer, distributor, or dispenser, or which substance is falsely purported to be or
11 represented to be one of the controlled substances by a manufacturer, distributor, or dispenser.
12 (11) “CRT” means cathode ray tube used to impose visual information on a screen.
13 (12) “Deliver” or “delivery” means the actual, constructive, or attempted transfer of a
14 controlled substance or imitation controlled substance, whether or not there exists an agency
15 relationship.
16 (13) “Department” means the department of health of this state.
17 (14) “Depressant or stimulant drug” means:
18 (i) A drug that contains any quantity of:
19 (A) Barbituric acid or derivatives, compounds, mixtures, or preparations of barbituric acid;
20 and
21 (B) “Barbiturate” or “barbiturates” includes all hypnotic and/or somnifacient drugs,
22 whether or not derivatives of barbituric acid, except that this definition shall not include bromides
23 and narcotics.
24 (ii) A drug that contains any quantity of:
25 (A) Amphetamine or any of its optical isomers;
26 (B) Any salt of amphetamine and/or desoxyephedrine or any salt of an optical isomer of
27 amphetamine and/or desoxyephedrine, or any compound, mixture, or preparation of them.
28 (iii) A drug that contains any quantity of coca leaves. “Coca leaves” includes cocaine, or
29 any compound, manufacture, salt, derivative, mixture, or preparation of coca leaves, except
30 derivatives of coca leaves, that do not contain cocaine, ecgonine, or substance from which cocaine
31 or ecgonine may be synthesized or made.
32 (iv) Any other drug or substance that contains any quantity of a substance that the attorney
33 general of the United States, or the director of health, after investigation, has found to have, or by
34 regulation designates as having, a potential for abuse because of its depressant or stimulant effect
LC001419/SUB A - Page 15 of 20

1 on the central nervous system.
2 (15) “Director” means the director of health.
3 (16) “Dispense” means to deliver, distribute, leave with, give away, or dispose of a
4 controlled substance to the ultimate user or human research subject by or pursuant to the lawful
5 order of a practitioner, including the packaging, labeling, or compounding necessary to prepare the
6 substance for that delivery.
7 (17) “Dispenser” is a practitioner who delivers a controlled substance to the ultimate user
8 or human research subject.
9 (18) “Distribute” means to deliver (other than by administering or dispensing) a controlled
10 substance or an imitation controlled substance and includes actual constructive, or attempted
11 transfer. “Distributor” means a person who so delivers a controlled substance or an imitation
12 controlled substance.
13 (19) “Downtime” means that period of time when a computer is not operable.
14 (20) “Drug addicted person” means a person who exhibits a maladaptive pattern of
15 behavior resulting from drug use, including one or more of the following: impaired control over
16 drug use; compulsive use; and/or continued use despite harm, and craving.
17 (21) “Drug Enforcement Administration” means the Drug Enforcement Administration,
18 United States Department of Justice or its successor.
19 (22) “Federal law” means the Comprehensive Drug Abuse Prevention and Control Act of
20 1970, (84 stat. 1236) (see generally 21 U.S.C. § 801 et seq.), and all regulations pertaining to that
21 federal act.
22 (23) “Hardware” means the fixed component parts of a computer.
23 (24) “Hospital” means an institution as defined in chapter 17 of title 23.
24 (25) “Imitation controlled substance” means a substance that is not a controlled substance,
25 that by dosage unit, appearance (including color, shape, size, and markings), or by representations
26 made, would lead a reasonable person to believe that the substance is a controlled substance and,
27 which imitation controlled substances contain substances that if ingested, could be injurious to the
28 health of a person. In those cases when the appearance of the dosage unit is not reasonably sufficient
29 to establish that the substance is an “imitation controlled substance” (for example in the case of
30 powder or liquid), the court or authority concerned should consider, in addition to all other logically
31 relevant factors, the following factors as related to “representations made” in determining whether
32 the substance is an “imitation controlled substance”:
33 (i) Statement made by an owner, possessor, transferor, recipient, or by anyone else in
34 control of the substance concerning the nature of the substance, or its use or effect.
LC001419/SUB A - Page 16 of 20

1 (ii) Statements made by the owner, possessor, or transferor, to the recipient that the
2 substance may be resold for substantial profit.
3 (iii) Whether the substance is packaged in a manner reasonably similar to packaging of
4 illicit controlled substances.
5 (iv) Whether the distribution or attempted distribution included an exchange of or demand
6 for money or other property as consideration, and whether the amount of the consideration was
7 substantially greater than the reasonable value of the non-controlled substance.
8 (26) “Immediate precursor” means a substance:
9 (i) That the director of health has found to be, and by regulation designated as being, the
10 principal compound used, or produced primarily for use, in the manufacture of a controlled
11 substance;
12 (ii) That is an immediate chemical intermediary used, or likely to be used, in the
13 manufacture of those controlled substances; and
14 (iii) The control of which is necessary to prevent, curtail, or limit the manufacture of that
15 controlled substance.
16 (27) “Laboratory” means a laboratory approved by the department of health as proper to
17 be entrusted with controlled substances and the use of controlled substances for scientific and
18 medical purposes and for the purposes of instruction.
19 (28) “Manufacture” means the production, preparation, propagation, cultivation,
20 compounding, or processing of a drug or other substance, including an imitation controlled
21 substance, either directly or indirectly or by extraction from substances of natural origin, or
22 independently by means of chemical synthesis or by a combination of extraction and chemical
23 synthesis and includes any packaging or repackaging of the substance or labeling or relabeling of
24 its container in conformity with the general laws of this state except by a practitioner as an incident
25 to his or her administration or dispensing of the drug or substance in the course of his or her
26 professional practice.
27 (29) “Manufacturer” means a person who manufactures but does not include an apothecary
28 who compounds controlled substances to be sold or dispensed on prescriptions.
29 (30) “Marijuana” means all parts of the plant cannabis sativa L., whether growing or not;
30 the seeds of the plant; the resin extracted from any part of the plant; and every compound,
31 manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin, but shall not
32 include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the
33 seeds of the plant, any other compound, manufacture, salt, derivative, mixture, or preparation of
34 mature stalks, (except the resin extracted from it), fiber, oil or cake, or the sterilized seed from the
LC001419/SUB A - Page 17 of 20

1 plant which is incapable of germination. Marijuana shall not include “industrial hemp” or
2 “industrial hemp products” which satisfy the requirements of chapter 26 of title 2, nor shall it
3 include products that have been approved for marketing as a prescription medication by the U.S.
4 Food and Drug Administration and legally prescribed.
5 (31) “Narcotic drug” means any of the following, whether produced directly or indirectly
6 by extraction from substances of vegetable origin, or independently by means of chemical synthesis
7 or by a combination of extraction and chemical synthesis:
8 (i) Opium and opiates.
9 (ii) A compound, manufacture, salt, derivative, or preparation of opium or opiates.
10 (iii) A substance (and any compound, manufacture, salt, derivative, or preparation of it)
11 that is chemically identical with any of the substances referred to in subsections 31(i) and (31)(ii).
12 (iv) Any other substance that the attorney general of the United States, or his or her
13 successor, or the director of health, after investigation, has found to have, and by regulation
14 designates as having, a potential for abuse similar to opium and opiates.
15 (32) “Official written order” means an order written on a form provided for that purpose
16 by the Drug Enforcement Administration under any laws of the United States making provision for
17 an official form, if order forms are authorized and required by federal law, and if no order form is
18 provided, then on an official form provided for that purpose by the director of health.
19 (33) “Opiate” means any substance having an addiction-forming or addiction-sustaining
20 liability similar to morphine or being capable of conversion into a drug having addiction-forming
21 or addiction-sustaining liability.
22 (34) “Opioid analgesics” means and includes, but is not limited to, the medicines
23 buprenophine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine,
24 methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene as well
25 as their brand names, isomers, and combinations, or other medications approved by the department.
26 (35) “Opioid antagonist” means naloxone hydrochloride and any other drug approved by
27 the United States Food and Drug Administration for the treatment of opioid overdose.
28 (36) “Opium poppy” means the plant of the species papaver somniferum L., except the
29 seeds of the plant.
30 (37) “Ounce” means an avoirdupois ounce as applied to solids and semi-solids, and a fluid
31 ounce as applied to liquids.
32 (38) “Person” means any corporation, association, partnership, or one or more individuals.
33 (39) “Physical dependence” means a state of adaptation that is manifested by a drug class
34 specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction,
LC001419/SUB A - Page 18 of 20

1 decreasing blood level of the drug, and/or administration of an antagonist.
2 (40) “Poppy straw” means all parts, except the seeds, of the opium poppy, after mowing.
3 (41) “Practitioner” means:
4 (i) A physician, osteopath, dentist, chiropodist, veterinarian, scientific investigator, or other
5 person licensed, registered, or permitted to distribute, dispense, conduct research with respect to or
6 to administer a controlled substance in the course of professional practice or research in this state.
7 (ii) A pharmacy, hospital, or other institution licensed, registered, or permitted to distribute,
8 dispense, conduct research with respect to, or to administer a controlled substance in the course of
9 professional practice or research in this state.
10 (42) “Printout” means a hard copy produced by computer that is readable without the aid
11 of any special device.
12 (43) “Production” includes the manufacture, planting, cultivation, growing, or harvesting
13 of a controlled substance.
14 (44) “Qualified law enforcement agency” means the U.S. Food and Drug Administration,
15 Drug Enforcement Administration, Federal Bureau of Investigation, Office of Inspector General of
16 the U.S. Department of Health & Human Services, or the Medicaid Fraud and Patient Abuse Unit
17 in the Office of the Attorney General.
18 (45) “Researcher” means a person authorized by the director of health to conduct a
19 laboratory as defined in this chapter.
20 (46) “Sell” includes sale, barter, gift, transfer, or delivery in any manner to another, or to
21 offer or agree to do the same.
22 (47) “Software” means programs, procedures, and storage of required information data.
23 (48) “Synthetic drugs” means any synthetic cannabinoids or piperazines or any synthetic
24 cathinones as provided for in schedule I.
25 (49) “Ultimate user” means a person who lawfully possesses a controlled substance for his
26 or her own use or for the use of a member of his or her household, or for administering to an animal
27 owned by him or her or by a member of his or her household.
28 (50) “Wholesaler” means a person who sells, vends, or distributes at wholesale, or as a
29 jobber, broker agent, or distributor, or for resale in any manner in this state any controlled
30 substance.
31 SECTION 4. This act shall take effect upon passage.
========
LC001419/SUB A
========
LC001419/SUB A - Page 19 of 20

EXPLANATION
BY THE LEGISLATIVE COUNCIL
OF
A N A C T
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT
***
1 This act would revise sections of the uniform controlled substances act to remove specific
2 opioid dosage requirements and revise the uniform controlled substances act in accordance with
3 current standards of professional practice and would repeal chapter 37.4 of title 5 relating to
4 intractable pain treatment.
5 This act would take effect upon passage.
========
LC001419/SUB A
========
LC001419/SUB A - Page 20 of 20

[DELETED: TATE  OF  RHODE  ISLAND S C 2 e " C S A a h a t r a f 2 U u ( “ p m t n p p r t a n c t ( a ( a ( w ( m w d o d e t t t d n i a c t]
[DELETED:  ( w c s a c o d b a r p a i r c p ( a ( s p p s i ( i ( “ m p e d c o m i ( s ( d b ( a ( l i o a b o ( (]
[DELETED:  c s o i c s w o n t e a a r ( ( ( ( a ( “ o “ i a h a s d w a ( ( ( a ( a c m s d m o p o c l e d o ( g r o ( ( c o s ( u ( “ m t d ( t b a o d a c s o a i c s a i a c o a i (]
[DELETED:  ( b d ( “ E A m t D E A ( o t ( ( ( “ c s m a s t i n a c s r s i r e a m ( c ( S m b t o p o t t t r t t s ( i ( f s ( ( p c u o p p f u i t m o a c s ( o]
[DELETED:  ( c ( t m ( “ m t p p p c c o p o a d o o s i a i c s e d o i o b e f s o n o o i s i t p ( “ m a p w m b d n i a a ( n m i s m p w i i o g M s n i “ h o “ i F ( “ d m a o t f w p d o i b e f s o v o o i b m o c ( ( ( t ( t s o t d o h a i h f t h a b r]
[DELETED:  d ( “ w m a o w o f p f p p o ( l o ( m b m b c h h l m m m n o o p p a ( b ( n f ( s ( f ( “ m a c a p o o o m i ( c d ( “ s m a p e t s o t o p a m ( ( p t (]
[DELETED:  d p ( a ( “ i t m p c g o h ( l ( t ( d ( “ d m a s c o p o a s ( p i a d a i b t p m r A o u i n ( h a ( a s 2 ( A p P g f a i c o h p s t ( O t m o b i f a p u t n t o ( p o]
[DELETED:  s f ( a o t r a w o u a t r w t p i n T p ( t r c 3 m s c r p i p p a w a c d o p e m h b a ( t ( s s d i a i l d b ( T d o h s d r f p p o a p]
[DELETED:  ( p ( m d o w ( a ( t p a ( w o ( m ( b ( i i ( s ( ( d ( o ( ( ( (]
[DELETED:  o ( A p i n s t p a d o a ( e a o ( p 2 A o p t p a a d — C ( A p i g f a i h p m c h d c s w r t t C C P G f P ( T d o h m p t r a r n t e t p o t s a e t r g p m a w a c d p o n h c i o c i r ( a ( p n a s r o r t t c m p a o d c s n p b l f a t p t a p d d ( d d i]
[DELETED:  s r t ( p k t b u t p a o d c s n ( d ( t ( n t ( F t k c a a r o c s r p s U d d r ( o A ( t e ( T d o h m p t r a r n t e S h C I 5]
[DELETED:  T 5 F ( s p p s i ( ( d o t ( “ m h p l t d d o a 1 ( i 5 ( A p m p a o d c s n p a p s f p a o d c s w p a p d ( t r ( p k t b u t p a o d c s]
[DELETED:  n ( t t s b ( I c w § 2 a 2 t d o h m p p w i o c i p a t o r t a a s ( d ( t ( n t ( F t k c a a r o c s r p s U d d r ( o A ( o 8 ( n f t]
[DELETED:  d s f a c s w p o d f a t i r S C 2 U u ( p ( ( w ( m w d o d e t t t d n i a c t ( w c s a c o d b a r p a i r c p ( h ( l p ( “ m p e d c o m i ( u (]
[DELETED:  d b ( p ( o n t t o r ( ( c s o i c s w o n t e a a r ( ( ( ( a ( “ o “ i a h a s d w a ( ( ( a ( a c m s d m o p o c l e d o ( g r]
[DELETED:  o ( ( “ m t d d l w g a o d o a c o s ( o ( s o a i c s a i a c o a t c ( ( “ a p m a p w e a m p o b d ( U ( 1 f ( ( ( t m w h t p r t ( c]
[DELETED:  ( S m b t o p o t t t r t t s ( i ( f s ( ( p c u o p p f u i t m o a c s ( T i a i c i u o l t b u i t m ( c ( b m ( “ m t p p p c c o p o a d o o s i a i c s e d o i o b e f s o n o o i s i t p ( w ( t s o t p t r e f a p o t p a e c m i s m]
[DELETED:  p w i i o g M s n i “ h o “ i F ( b o ( ( ( t ( s o t d o h a i h f t h a b r d ( b a p ( l o ( “ a m a i b i n l t t m b b c h h l m m a ( t ( s ( o ( ( s]
[DELETED:  d ( ( ( p t ( d p ( o ( o ( D t i ( “ m a p a b t d o h t c a l ( o ( ( c ( o o ( j b a o d o f r i a m i t s a c s S]
[DELETED:  T o c i T]